3 results
Approved WMOPending
To investigate the long-term safety, tolerability and acceptability of Nasalfent in the treatment BTCP
Approved WMOCompleted
The objective of this investigation is to describe visual outcomes and assess the safety at 12 months (330 - 420 days) post bilateral implantation of the AcrySof® IQ PanOptix* Presbyopia correcting IOL Model TFNT00.
Approved WMOCompleted
The main purpose of this pilot study is to investigate the feasibility of fluorescence imaging using cetuximab-IRDye800CW for intraoperative margin assessment in patients with cutaneous squamous cell carcinoma.